Crispr Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $35,000 | $602 | $517 | $504 |
Gross Profit | 35,000 | -10,551 | -56,459 | -51,295 |
EBITDA | -59,746 | -105,391 | -146,415 | -135,754 |
EBIT | -64,588 | -110,191 | -151,260 | -140,587 |
Net Income | -37,311 | -85,942 | -126,408 | -116,591 |
Net Change In Cash | 35,000 | 602 | 517 | 504 |
Free Cash Flow | -50,285 | -107,132 | -96,289 | 109,031 |
Cash | 298,257 | 225,670 | 484,472 | 707,427 |
Basic Shares | 84,359 | 85,234 | 84,920 | 81,794 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $35,000 | $371,206 | $436 | $913,081 |
Gross Profit | 37,314 | 240,956 | -109,814 | 913,081 |
EBITDA | -466,566 | -202,701 | -648,989 | 391,481 |
EBIT | -222,538 | -673,161 | 373,528 | |
Net Income | -366,252 | -153,610 | -650,175 | 377,661 |
Net Change In Cash | 35,000 | 371,206 | 436 | 913,081 |
Cost of Revenue | -715,804 | -245,513 | ||
Free Cash Flow | -144,675 | -272,345 | -532,929 | 457,267 |
Cash | 298,257 | 389,477 | 211,885 | 923,031 |
Basic Shares | 84,359 | 79,220 | 77,746 | 80,393 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.44 |
2024-09-30 | -$1.01 |
2024-06-30 | -$1.49 |
2024-03-31 | -$1.43 |
